Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade

Schizophr Res. 2010 Jun;119(1-3):160-3. doi: 10.1016/j.schres.2009.12.005. Epub 2010 Jan 6.

Abstract

A recent Finnish study reported that long-term cumulative exposure to any antipsychotic treatment was related to lower mortality than was no drug exposure. We hypothesize that the antipsychotic 5-HT2A receptor blockade might protect from ischemic heart disease and buffer the deleterious metabolic effects of antipsychotics. The 5-HT2A receptor may be involved in vascular smooth muscle contraction, coronary artery spasms, platelet aggregation and thrombus formation. 5-HT2A receptor blockade might protect from ischemic heart disease by decreasing platelet aggregation and myocardium hypertrophy. Long-term follow-up studies are needed to clearly establish the long-term contribution of the various antipsychotic drugs to ischemic heart disease, and to explore our hypothesis that 5-HT2A receptor blockade may be protective for cardiovascular disease.

MeSH terms

  • Antipsychotic Agents / administration & dosage*
  • Antipsychotic Agents / adverse effects
  • Cause of Death
  • Humans
  • Long-Term Care
  • Myocardial Ischemia / mortality*
  • Myocardial Ischemia / prevention & control*
  • Receptors, Histamine H1 / drug effects
  • Risk
  • Schizophrenia / drug therapy*
  • Schizophrenia / mortality*
  • Serotonin 5-HT2 Receptor Antagonists*
  • Weight Gain

Substances

  • Antipsychotic Agents
  • Receptors, Histamine H1
  • Serotonin 5-HT2 Receptor Antagonists